

Product Data Sheet

Mps1-IN-3 hydrochloride

Cat. No.: HY-12401A CAS No.: 2989453-29-2 Molecular Formula: $\mathsf{C}_{26}\mathsf{H}_{32}\mathsf{ClN}_7\mathsf{O}_4\mathsf{S}$

Molecular Weight: 574.09 Target: Mps1

Pathway: Cell Cycle/DNA Damage; Cytoskeleton Storage: -20°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 20 mg/mL (34.84 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.7419 mL	8.7094 mL	17.4189 mL
	5 mM	0.3484 mL	1.7419 mL	3.4838 mL
	10 mM	0.1742 mL	0.8709 mL	1.7419 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Mps1-IN-3 hydrochloride is a potent and selective Mps1 inhibitor with an IC $_{50}$ value of 50 nM. Mps1-IN-3 hydrochloride can inhibit the proliferation of glioblastoma cells, and effectively sensitizes glioblastomas to Vincristine in orthotopic glioblastoma xenograft model ^[1] .
IC ₅₀ & Target	IC ₅₀ : 50 nM (Mps1) ^[1]
In Vitro	Mps1-IN-3 hydrochloride (0.3-10 μ M) inhibits the marker of mitotic cells cyclin B in a dose-dependent manner ^[1] . Mps1-IN-3 hydrochloride (2 μ M) causes a dose-dependent escape from a checkpoint-mediated mitotic arrest ^[1] . Mps1-IN-3 hydrochloride (1-15 μ M) inhibits the proliferation of U251 glioblastoma cells with an IC ₅₀ value of ~5 μ M ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Mps1-IN-3 hydrochloride (2 mg/kg; IV, twice a week, for 3 weeks) effectively sensitizes glioblastomas to Vincristine in orthotopic glioblastoma xenograft models ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Cell Metab. 2021 Jun 1;33(6):1111-1123.e4.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Tannous BA, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst. 2013 Sep 4;105(17):1322-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com